Vivian P. Bykerk, MD, an attending rheumatologist at the Hospital for Special Surgery (HSS), New York, and Susan M. Goodman, MD, an attending physician at HSS, discuss Janus kinase (JAK)-1 inhibitors in psoriatic arthritis (PsA), how to best approach risk-benefit treatment discussions for patients who may benefit from JAK-1 therapy, and the promise of precision medicine in treating PsA.
Special Collections
